➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Medtronic
Johnson and Johnson
Dow
McKinsey

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

MEDROL ACETATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Medrol Acetate, and when can generic versions of Medrol Acetate launch?

Medrol Acetate is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in MEDROL ACETATE is methylprednisolone acetate. There are forty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the methylprednisolone acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Medrol Acetate

A generic version of MEDROL ACETATE was approved as methylprednisolone acetate by TEVA PHARMS USA on February 23rd, 2005.

  Start Trial

Summary for MEDROL ACETATE
Drug patent expirations by year for MEDROL ACETATE

US Patents and Regulatory Information for MEDROL ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn MEDROL ACETATE methylprednisolone acetate OINTMENT;TOPICAL 012421-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn MEDROL ACETATE methylprednisolone acetate OINTMENT;TOPICAL 012421-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
McKinsey
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.